Clinical trials: Adverse Drug Reaction
Adverse Drug Reaction
Adverse Drug Reactions With Fatal Outcome
The purpose of this study is to determine the incidence of drug-related deaths in a university hospital during the year 2015
- Trial name
- NCT02838212
- Testing
- adverse drug reaction
- Volunteers
- 1,135 people
- Sponsor
- Germans Trias i Pujol Hospital
Adverse Drug Reaction (ADR), Polypharmacy Patients
IPGx PILOT Whole Genome Sequencing Extension Cohort
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make…
- Trial name
- NCT06766071
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Texas A&M University
Seizures
Pathogenesis of Adverse Drug Reactions
The purpose of the study is to examine the individual metabolic profiles of pediatric patients receiving carbamazepine or valproate therapy, in an attempt to determine identities of the reactive metabolites or, alternatively, the…
- Trial name
- NCT00224952
- Testing
- No intervention; Urine Collection
- Where
- 3 sites in United States
- Volunteers
- 274 people
- Sponsor
- Children's Mercy Hospital Kansas City
Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
This study aims to analyze the effects of long-acting versus short-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer patients.
- Conditions
- Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced, Epithelial Ovarian Cancer, Colony Stimulating Factors Adverse Reaction
- Trial name
- NCT04101760
- Testing
- Long-acting granulocyte colony stimulating factor, Short-acting granulocyte colony stimulating factor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Lei Li
Adverse Drug Reaction (ADR)
The INTEGRATE Study: Integrated Pharmacogenetics, TDM and Active Pharmacovigilance as Innovative Tools for the Optimisation and Appropriateness of Drug Therapy
The primary goal of this observational study is to evaluate the feasibility of implementing a multidisciplinary approach based on pharmacogenetics, TDM (Therapeutic Drug Monitoring) and MedReview into the clinical practice in…
- Trial name
- INTEGRATE (NCT06822959)
- Testing
- Pharmacogenetics, TDM and MedReview
- Where
- 2 sites in Italy
- Volunteers
- 450 people
- Sponsor
- Direzione centrale salute, politiche sociali e disabilità
Arthritis, Cancer
Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction
Immune checkpoint inhibitors (ICIs) might have high grade immune-related adverse events (irAEs) from rhumatologic, endocrinologic, cardiac or other system origin.
- Conditions
- Arthritis, Cancer, Cardiac Disease, Endocrine System Diseases
- Trial name
- CHIMeRA (NCT03492242)
- Testing
- Immune checkpoint inhibitor
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Kidney Impairment
Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy
This study is to investigate blood and urine kidney injury markers (especially Uromodulin) in pediatric cancer patients treated with nephrotoxic chemotherapy.
- Trial name
- Kid-MaCareOnco (NCT04308642)
- Testing
- blood test for renal biomarkers, urine test for renal biomarkers
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- University Hospital, Basel, Switzerland
Adverse Drug Event
Adverse Drug Events at Emergency Department
Emergency departments (EDs) are a crucial element of the health care systems at interface between hospital and communities. The goals of the ED are to make an initial diagnosis and deliver urgent and critical care 24 hour per day…
- Trial name
- ADEsED (NCT03442010)
- Testing
- Detection of adverse drug events
- Where
- France
- Volunteers
- 13,453 people
- Sponsor
- University Hospital, Montpellier
Adverse Drug Related Events
Development of a Screening Strategy for Community-based Adverse Drug Related Events in the Emergency Department
Adverse Drug Related Events (ADREs) are a leading cause of Emergency Department (ED) visits in Canada. However emergency physicians recognize only half of all ADREs in patients presenting to the ED, missing opportunities to…
- Trial name
- NCT00727610
- Where
- 2 sites in Canada
- Volunteers
- 1,588 people
- Sponsor
- University of British Columbia
Drug-Related Side Effects and Adverse Reaction, Digoxin Overdose
Introducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults
The intervention consists of introducing computerized alerts into the electronic medical record of the CSAPG (MIRA software), which are triggered when a physician prescribes digoxin at a dose higher than the recommended amount…
- Trial name
- Aldigo (NCT07008144)
- Testing
- Digoxin alarm
- Where
- 2 sites in Spain
- Volunteers
- 5,954 people
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Polypharmacy Patients
Assessment of a Novel Algorithm System for Polypharmacy Patient Medication Safety and Consultation
The aim of this study is to determine if insights based on the analysis of historical data of multidrug patients' electronic health records, by a novel system and algorithm, is noninferior to a clinical pharmacist analysis and…
- Trial name
- NCT05589870
- Testing
- Multi-drug analysis of polypharmacy treatment
- Where
- Israel
- Volunteers
- 91 people
- Sponsor
- MDI Health
Adverse Drug Reactions, Clinical Decision Support
Multi-Agent Collaborative ADR Prediction With Human-Machine Decision Comparison
This study develops a multi-agent collaborative prediction model to forecast adverse drug reactions using real-world clinical medical records.
- Trial name
- NCT07808866
- Testing
- Retrospective medical record data analysis only, no clinical intervention
- Where
- 2 sites in China
- Volunteers
- 20,000 people
- Sponsor
- Peking University Third Hospital
Adverse Reaction to Drug
Intensive Monitoring Scheme of Lidocaine Cataplasms
In this center, retrospective research methods are used to collect data. Patients who had used Lidocaine Cataplasms at least once were included consecutively.
- Trial name
- NCT05645302
- Testing
- Lidocaine Cataplasms
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Qianfoshan Hospital
Cardiovascular Complication, Cardiovascular Insufficiency
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer…
- Conditions
- Cardiovascular Complication, Cardiovascular Insufficiency, Cardiac Complication, Oncologic Complications
- Trial name
- NEOCARDIO (NCT03882580)
- Testing
- Anti-Cancer Agents
- Where
- 3 sites in France
- Volunteers
- 5,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Complications of Surgical and Medical Care: General Terms, Adverse Reaction to Drug
The Thai Surgical Intensive Care Study (Thai-SICU Study)
The study observed the 28 days mortality of 9 participated University base surgical intensive care unit (SICU) as well as the occurrence of adverse events in SICU.
- Conditions
- Complications of Surgical and Medical Care: General Terms, Adverse Reaction to Drug, Sequelae of External Causes of Morbidity and Mortality, Critical Illness
- Trial name
- THAI-SICU (NCT01354197)
- Where
- 9 sites in Thailand
- Volunteers
- 4,652 people
- Sponsor
- Royal College of Anesthesiologists of Thailand
Non-steroidal Anti-inflammatory Drug Adverse Reaction
Research for Prevention and Treatment of NSAIDs Related Gastrointestinal Side Effects
We aim to evaluate the protective effects of eradication of HP and continue using Geranylgeranylacetone (GGA) on NSAIDs related gastroenterological lesions.
- Trial name
- NCT01547559
- Testing
- part1:teprenone, part1:EAC-T, part1:EA-EMC-T
- Where
- 2 sites in China
- Volunteers
- 369 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Toxic Epidermal Necrolysis, Immunotherapy
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
Toxic Epidermal Necrolysis (TEN) are rare diseases that are dermatologic emergencies characterized by widespread epidermal necrosis and sloughing of skin. A hundred patients are affected each year in France.
- Conditions
- Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)
- Trial name
- NET-CD38 (NCT07110662)
- Testing
- DARATUMUMAB (DARZALEX®)
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Hospices Civils de Lyon
Epileptic Seizures Related to Drugs, SARS-CoV-2 Acute Respiratory Disease
Epileptic Seizure in Epilepsy Patients After SARS-CoV-2 Vaccination
Background and Objectives: Seizure attack is one of adverse effects of vaccination in epileptic patients, the risk of which after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inoculation was elucidated in the…
- Conditions
- Epileptic Seizures Related to Drugs, SARS-CoV-2 Acute Respiratory Disease, Vaccine Adverse Reaction
- Trial name
- NCT05341713
- Testing
- inactive SARS-Cov-2 vaccine
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Xijing Hospital
Statin Therapy, Statin Adverse Reaction
DESIFOR-EXPAND (MHIF)
The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients with prior statin intolerance
- Conditions
- Statin Therapy, Statin Adverse Reaction, Statin
- Trial name
- NCT06804980
- Testing
- Rosuvastatin (Crestor)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Minneapolis Heart Institute Foundation
Pain, Quality of Life
Simultaneous RZV and aIIV4 Vaccination
The overall aim of the study is to compare the safety of simultaneous Zoster Vaccine Recombinant, Adjuvanted (RZV) (SHINGRIX®) and Quadrivalent Influenza Vaccine, Adjuvanted (FLUAD®) versus simultaneous Zoster Vaccine…
- Conditions
- Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
- Trial name
- NCT05007041
- Testing
- FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
- Where
- 2 sites in United States
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Duke University